H.C. Wainwright initiated coverage of FibroGen (FGEN) with a Buy rating and $10 price target The company’s lead asset, FG-3246, is a novel antibody drug conjugate targeting CD46 expressing tumors, the analyst tells investors in a research note. The firm says FibroGen’s pipeline “could be a whole new ball game” in metastatic castration-resistant prostate cancer and beyond.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.